Bezafibrate
Bezafibrate is a PPARα agonist that is clinically used to lower LDL and triglyceride levels and to increase HDL levels. Bezafibrate exhibits anti-hyperlipidemic, cardioprotective, anti-diabetic, anti-osteoporotic, and anticancer chemotherapeutic activities. When administered clinically, bezafibrate decreases risk of myocardial infarction and cardiac mortality; it also decreases the incidence and delays the onset of type 2 diabetes. Bezafibrate promotes bone formation by activating proliferation and differentiation of osteoblasts in vitro in an AMPK- and PPARβ-dependent manner. In animal models of non-small cell lung cancer (NSCLC), bezafibrate decreases angiogenesis and tumor growth through downregulation of Cyp2c expression or activity.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18843937
| Cas No. |
41859-67-0 |
|---|---|
| Purity |
≥98% |
| Formula |
C19H20ClNO4 |
| Formula Wt. |
361.82 |
| Chemical Name |
2-[4-[2-[(4-Chlorobenzoyl)amino]ethyl]phenoxy]-2- methylpropanoic acid |
| IUPAC Name |
2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid |
| Synonym |
Befizal; Bezatol; Cedur; Difaterol |
| Melting Point |
186°C |
| Solubility |
Soluble in DMSO (50mg/mL). |
| Appearance |
White or Almost White Powder |
Skrypnyk N, Chen X, Hu W, et al. PPARα activation can help prevent and treat non-small cell lung cancer. Cancer Res. 2014 Jan 15;74(2):621-31. PMID: 24302581.
Zhong X, Xiu LL, Wei GH, et al. Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation. Acta Pharmacol Sin. 2011 May;32(5):591-600. PMID: 21499286.
Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005 May 23;165(10):1154-60. PMID: 15911729.
Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004 May 11;109(18):2197-202. PMID: 15123532.
Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000 Jul 4;102(1):21-7. PMID: 10880410.
